

Supplementary Table 2. Subgroup sensitivity analysis

Outcome	Pooled rate (95% confidence interval; I^2)	
	Geography (USA, Asia & others)	Sample size (<20 & >20)
<i>En bloc</i> resection	USA: 93% (84.1–97.1; 7%) 3 studies Asia: 93.4% (85.9–97; 0%) 6 studies Others: 91.6% (72.7–97.8; 51%) 3 studies	<20: 87.8% (76.9–94; 0%) 6 studies >20: 94.7% (90.1–97.2; 0%) 6 studies
R0 resection	USA: 83.5% (59.3–94.6; 61%) 2 studies Asia: 78.4% (66.6–86.9; 29%) 6 studies Others: 85.6% (59.4–96; 74%) 3 studies	<20: 74.9% (62.8–84.1; 0%) 5 studies >20: 86% (73.9–93; 67%) 6 studies
Curative resection	USA: 6.7% (2.2–18.7; 0%) 1 study Asia: 75.4% (55.8–88.2; 62%) 5 studies Others: 88.4% (42.3–98.8; 82%) 2 studies	<20: 71.6% (57.5–82.4; 0%) 4 studies >20: 73.9% (17.8–97.3; 94%) 4 studies
Bleeding	USA: 7.5% (3.1–16.7; 0%) 3 studies Asia: 5.3% (1.5–17.3; 42%) 6 studies Others: 10.8% (5.6–19.7; 1%) 3 studies	<20: 11.5% (5.1–24; 1%) 6 studies >20: 6.8% (3.3–13.3; 25%) 6 studies
Perforation	USA: 3.5% (1–11.5; 0%) 3 studies Asia: 6.6% (3.2–13.3; 0%) 6 studies Others: 4.7% (1.8–12; 0%) 3 studies	<20: 4.3% (1.4–12.6; 0%) 6 studies >20: 5.7% (3.1–10.1; 0%) 6 studies
Local recurrence	USA: 2.9% (0.7–10.8; 0%) 3 studies Asia: 5.4% (2.1–12.9; 0%) 6 studies Others: 2.6% (0.6–9.8; 0%) 3 studies	<20: 7.3% (2.9–17; 0%) 6 studies >20: 2% (0.7–5.1; 0%) 6 studies; $p=0.05$
Metachronous recurrence	USA: 10.3% (0.8–61.3; 71%) 2 studies Asia: 12.3% (5.1–26.9; 56%) 6 studies Others: 6.3% (2.8–13.8; 0%) 3 studies	<20: 17.2% (7.4–35; 39%) 5 studies >20: 7.5% (3–17.3; 64%) 6 studies
Additional surgery after ESD	USA: 15.7% (2.9–54; 81%) 3 studies Asia: 15.7% (9.7–24.5; 6%) 6 studies Others: 8.4% (3.9–17.1; 5%) 3 studies	<20: 15.9% (8.7–27.5; 0%) 6 studies >20: 12.6% (5.7–25.7; 74%) 6 studies

ESD, endoscopic submucosal dissection.